Every material Form 8-K HARROW, INC. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Harrow reported record third-quarter 2026 revenue of $99.3 million, up 39% year over year, and GAAP net income of $9.8 million, which included a $5.0 million litigation settlement gain. The company reaffirmed its full-year revenue guidance of $350 million to $365 million but lowered its Adjusted EBITDA guidance from $80 million to $100 million to more than $40 million, citing a first-half revenue shortfall, lower gross margins and higher spending.
Q3 2026 revenue of $99.3 million, up 39% year over year; branded revenue of $83.5 million.
GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, versus a net loss of $17.3 million in Q2 2026.
Full-year 2026 Adjusted EBITDA guidance cut from $80 million to $100 million to more than $40 million; revenue guidance of $350 million to $365 million reaffirmed.
Cash and cash equivalents were $75.3 million as of September 30, 2026.
Harrow completed its acquisition of worldwide rights to TYRVAYA nasal spray from Viatris on October 1, 2026, excluding Japan, paying $30 million in cash at closing funded from cash on hand. The company may also pay up to $70 million in contingent milestone payments tied to TYRVAYA net sales, and it expects TYRVAYA to contribute more than $30 million in revenue in 2027.
Closing payment of $30.0 million in cash, funded with cash on hand, with the price fixed after the net working capital adjustment was eliminated
Up to $70.0 million in contingent milestone payments tied to net sales over twelve-month periods ending on or before December 31, 2029
Viatris keeps Japanese commercial rights and will pay Harrow tiered royalties on Japanese net sales
Harrow expects approximately 40 Viatris personnel to join its Ocular Surface commercial team in the fourth quarter of 2026
Randall E. Pollard stopped serving as Harrow's Chief Accounting Officer and principal accounting officer effective September 4, 2026. The board named President and Chief Financial Officer Andrew R. Boll to also serve as principal accounting officer, with no additional compensation for that role.
Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer effective September 4, 2026.
Andrew R. Boll, President and Chief Financial Officer, was designated principal accounting officer effective upon Pollard's departure.
Boll will receive no additional compensation for the principal accounting officer role.
Details required for Boll are incorporated by reference from the proxy statement filed April 24, 2026.
Harrow reported second-quarter 2026 revenue of $70.7 million, up 11% from a year earlier, but posted a net loss of $17.3 million, or $0.46 per share, compared with net income of $5.0 million a year earlier. The company reiterated its full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA, and said the TYRVAYA acquisition is expected to close in the second half of 2026.
Q2 2026 revenue of $70.7 million, up 60% from $44.2 million in Q1 2026 and up 11% from $63.7 million a year earlier.
Adjusted EBITDA loss of $1.2 million in Q2 2026, compared with positive Adjusted EBITDA of $17.0 million in Q2 2025.
Full-year 2026 guidance reiterated: $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA.
Cash and cash equivalents of $83.9 million and loans payable of $292.4 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HARROW, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →